Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.35 |
| ▸ | CBS | P35520 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.30 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22771248 | 0.98 | HSD17B10 (0.35) | PTGS1TSHRCTHCBSTHPO | |
| SCHEMBL2829186 | 0.87 | — | — | |
| SCHEMBL23733923 | 0.87 | CYP2C19 (0.42) | PTGS1TSHRCTHCBSTHPO | |
| SCHEMBL45305 | 0.82 | TSHR (0.47) | PTGS1TSHRCTHCBSTHPO | |
| SCHEMBL23733934 | 0.80 | CYP2C19 (0.38) | THRBEPHX2CYP2C19BLMHSD17B10 | |
| SCHEMBL12666923 | 0.79 | CYP2C19 (0.38) | PTGS1TSHRCTHCBSTHPO | |
| SCHEMBL22445194 | 0.79 | LMNA (0.41) | TSHRBLMPMP22HSD17B10LMNA | |
| SCHEMBL2551593 | 0.79 | LMNA (0.41) | TSHRBLMPMP22HSD17B10LMNA | |
| SCHEMBL30411802 | 0.79 | LMNA (0.41) | TSHRBLMPMP22HSD17B10LMNA | |
| SCHEMBL6526724 | 0.79 | TDP1 (0.42) | PTGS1TSHRCTHCBSTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-9808011-B2 | Pentacyclic triterpene compounds and uses thereof | BIOVECTRA INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9808011-B2 | Pentacyclic triterpene compounds and uses thereof | BIOVECTRA INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-20160165892-A1 | PENTACYCLIC TRITERPENE COMPOUNDS AND USES THEREOF | AGILENT TECHNOLOGIES, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160165892-A1 | PENTACYCLIC TRITERPENE COMPOUNDS AND USES THEREOF | AGILENT TECHNOLOGIES, INC. | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160165892-A1 | PENTACYCLIC TRITERPENE COMPOUNDS AND USES THEREOF | GGPS1, LSS, ERG28 | PTGS1 371/4885TSHR 3279/4885CTH 2796/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | PTGS1 2912/4885TSHR 27/4885CTH 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.